TWK10® sports probiotic is an innovative strain L. plantarum and is the first probiotic clinically proven to increase exercise endurance by up to 75% in athletes of all levels.
Learn how TWK10® sports probiotic can help you break through in the competitive global sports and active nutrition categories.

Muenchensteinerstrasse 38
Basel
4002
Switzerland
HEALTH CATEGORIES
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.
Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.
Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

BUSINESS NEWS
Weekly Roundup: Lonza and IBF create framework agreement, Kemin expands operations to Mexico
27 May 2022 --- This week in nutrition news, Lonza and Israel Biotech Fund (IBF) have partnered for a two-year agreement to support Israeli-based companies with biologics and small molecule development. Kemin Industries, a global... Read More
BUSINESS NEWS
Weekly Roundup: Lonza sells Quakertown site, GOED appoints new exec
06 May 2022 --- This week in nutrition news, Lonza has agreed to sell its US-based Quakertown site to industry investors for an undisclosed amount. The Global Organization for eicosapentaenoic acid (EPA) and docosahexaenoic acid... Read More
NUTRITION & HEALTH NEWS
Lonza’s collagen improves joint flexibility by ten years, study finds
04 May 2022 --- A randomized, double-blind clinical study has shown that a 40 mg daily dose of Lonza Capsules & Health Ingredients UC-II undenatured type II collagen can significantly reverse joint flexibility degradation and... Read More
NUTRITION & HEALTH NEWS
28 Apr 2022 --- As consumers take a more holistic approach to their health, functional ingredients like collagen continue to rise in popularity. Industry experts address emerging collagen formats fueled by the need for increased... Read More
REGULATORY NEWS
Industry welcomes EU sustainability reporting proposal to channel investment toward environment
21 Mar 2022 --- Large companies in the EU may soon need to publicly disclose detailed information on the way they manage social and environmental risks. Following this proposal from the European Parliament, which aims to increase... Read More

Lonza launches white titanium dioxide-free hard gelatin capsules
16 May 2022 --- Amid toughening regulations surrounding titanium dioxide (TiO2) as a whitening ingredient, Lonza is expanding its Capsugel offering to meet TiO2-free requirements for food supplements in the EU. The company’s global product manager Julien Lamps details the opportunities and challenges surrounding the opacifying technology.
15 Mar 2022 --- In light of the EU’s ban on titanium dioxide, Anne Holderbach explores Lonza’s alternatives for capsules, which use iron oxide for an opaque effect and moderate UV protection. In terms of more vivid semi-opaque options, the company has also developed food-colored capsules.
Chr. Hansen demystifies “probiotics jungle” with global online education platform
31 May 2021 --- The “unharmonized” probiotics scene contributes to consumer confusion, which has motivated Chr. Hansen to launch a global online version of The Probiotics Institute. The one-stop-shop educational platform helps consumers navigate the “probiotics jungle” and demystify the human microbiome. Linda Neckmar, VP of commercial development, details why the company has developed a separate version for the Chinese market and how the move coincides with wider company strategies.
Forecasting the future of nutrition
22 Dec 2020 --- General health with an emphasis on digestion is set to reach new heights over the coming years as new research emerges, according to Roel van de Put, Lonza Capsules and Health Ingredients’ business development manager. Beauty-from-within, mobility, mood health and immunity will also be major forces shaping the nutritional realm, he predicts.
Titanium dioxide-free semi-opacifier reaches market ahead of French ban
02 Jan 2020 --- Lonza launched Vcaps Plus White Opal, its first commercially-available titanium dioxide-free semi-opaque capsule for food supplements, at CPhI Worldwide 2019. The launch precedes a ban on titanium dioxide, set to come into force in France, 2020. Stéphane Vouche, Marketing Manager at Lonza, predicts that increased scrutiny is bound to increase demand for clean label solutions in the space – something the new product offers with its avoidance of unnecessary chemicals, plasticizers and other elements.

05 Nov 2020 --- For today’s health-conscious and responsible consumers, Lonza’s Capsugel Plantcaps capsules provide the premier balance of product performance and convenience. This webinar dives into the latest market trends, as well as the science and regulatory landscape surrounding Plantcaps.
Live Better: Feel good, Stay mobile. Formulation strategies for today’s consumer
24 Jun 2020 --- Supplement users increasingly aspire to more sustainable, health-focused ideals and are on the hunt for high-quality, responsibly sourced products that help them to stay mobile and live better. In this webinar, Lonza experts delve into how these preferences extend across a range of emerging, on-demand consumer trends, from joint and cognitive health to probiotics and beauty-from-within.
Tio2 free: Clear path to compliance
08 Nov 2019 --- This webinar will discuss how food supplement makers can address the rising consumer demand for clean and clear label solutions in light of the changing regulatory environment regarding the use of titanium dioxide as an opacifier. It will also explore how Lonza’s new Vcaps® Plus WHITE OPAL® capsule is designed to perform and can support producers to meet this growing need in today’s market.
Moving with the times: a new generation joint health solution for today’s consumer
28 Mar 2019 --- The NutritionInsight webinar “Moving with the times: a new generation joint health solution for today’s consumer” offers insights into the changing consumer landscape, including the expectations of both aging and active consumers and rising demand for joint health solutions. Dominik Mattern of Lonza Capsugel discusses the science behind Lonza’s UC-II undenatured type II collagen ingredient, including its unique mode of action and how it can meet the needs of a new and growing consumer base. He presents a first look at Lonza’s new generation of ready-to-market innovative dosage forms and formulations that address mobility concerns related to healthy aging.
Driving growth in the joint health category: UC-II® undenatured type II collagen
19 Oct 2018 --- UC-II® undenatured type II collagen is a once-a-day joint health solution for the joint health market. Its small dose size and mode of action help make it the preferred choice among top food supplement manufacturers and retailers. Learn why UC-II® undenatured type II collagen is a success story and discover new ready-to-market solutions.